Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.

Saved in:
Bibliographic Details
Title: Dual-time-point [18F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy.
Authors: Thunold S; Department of Oncology, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. solthu@ous-hf.no.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. solthu@ous-hf.no.; Institute for Cancer Research, Oslo University Hospital, Postbox 4950 Nydalen, Oslo, 0424, Norway. solthu@ous-hf.no., Hernes E; Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Gyland Mikalsen LT; Department of Physics and Computational Radiology, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Farooqi S; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Öjlert ÅK; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia.; Medical School, The University of Western Australia, Perth, WA, Australia., Nowak AK; Medical School, The University of Western Australia, Perth, WA, Australia.; National Centre for Asbestos-Related Diseases, University of Western Australia, Perth, Australia.; Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia., Szejniuk WM; Clinical Cancer Research Center, Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Nielsen SS; Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark., Cedres S; Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Perdigo MS; Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain., Sørensen JB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Meltzer C; Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Helland Å; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Malinen E; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department of Physics, University of Oslo, Oslo, Norway., Haakensen VD; Department of Oncology, Oslo University Hospital, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Source: EJNMMI research [EJNMMI Res] 2026 Jun 20. Date of Electronic Publication: 2026 Jun 20.
Publication Type: Journal Article
Journal Info: Publisher: Springer Berlin Country of Publication: Germany NLM ID: 101560946 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2191-219X (Print) Linking ISSN: 2191219X NLM ISO Abbreviation: EJNMMI Res
Database: MEDLINE Ultimate
Description
ISSN:2191-219X
DOI:10.1186/s13550-026-01469-x